Veronese, Nicola
Briot, Karine
Guañabens, Nuria
Albergaria, Ben Hur
Alokail, Majed
Al-Daghri, Nasser
Bemden, Angie Botto-van
Bruyère, Olivier
Burlet, Nansa
Cooper, Cyrus
Curtis, Elizabeth M.
Ebeling, Peter R.
Halbout, Philippe
Hesse, Eric
Hiligsmann, Mickaël
Camargos, Bruno Muzzi
Harvey, Nicholas C.
Perez, Adolfo Diez
Radermecker, Régis Pierre
Reginster, Jean-Yves
Rizzoli, René
Siggelkow, Heide
Cortet, Bernard
Brandi, Maria Luisa
Funding for this research was provided by:
Università degli Studi di Palermo
Article History
Received: 24 June 2024
Accepted: 30 July 2024
First Online: 9 August 2024
Declarations
:
: NV has received personal honoraria from IBSA, Mylan, Nestlè, Viatris; NG has received honoraria for advisory board and lectures from Amgen, UCB, Gedeon-Richter and Theramex. BHA has received research grants from Eli Lilly, Merck & Co, Sanofi-Aventis, Novartis, Organon, Amgen, Radius; Honorarium for speaking from Eli Lilly, Amgen, Theramex, Momenta, Sanofi-Aventis; consulting fees from Theramex, Eli Lilly, Mantecorp, Amgen, UCB. OB has received consulting or lecture fees from Amgen, Aptissen, Biophytis, IBSA, Mylan, Novartis, Nutricia, Orifarm, Sanofi, UCB and Viatris. EH has received honoraria for advisory board meetings and lectures from Amgen, UCB, Eli Lilly, Kyowa Kirin, Ipsen, UCB, AgNovos, Binding Site and Theramex. EH is co-founder of Sirana Pharma. MH has received research grants (paid to institution) from Radius Health, and Angelini Pharma, lecture fees from IBSA (paid to institution) and Mylan Pharmaceuticals, and was grant advisor for Pfizer (paid to institution). EC has received lecture fees and conference support from Eli Lilly, Pfizer, Thornton & Ross and UCB. OB has received consulting or lecture fees from Amgen, Aptissen, Biophytis, IBSA, Mylan, Novartis, Nutricia, Orifarm, Sanofi, UCB and Viatris. JYR declares that he has received consulting fees or been on paid advisory boards for IBSA-Genevrier, Mylan, Radius Health, Pierre Fabre, Faes Pharma, Rejuvenate Biomed, Samumed, Teva, Theramex, Pfizer, Mithra Pharmaceuticals, received lecture fees when speaking at the invitation of the sponsor for IBSA-Genevrier, Mylan, Cniel, Dairy Research Council (DRC), Nutricia, Danone, Agnovos and received grant support from IBSA-Genevrier, Mylan, Cniel, Radius Health, TRB. RR declares that he has received fees as a speaker or consultant for Abiogen, Effryx, Nestlé, ObsEva and Theramex. HS reports advisory boards from Theramex (teriparatide generics, abaloparatide), UCB (romosozumab) and speaker engagements from stadapharm GmbH (teriparatide generics), Theramex (teriparatide generics, abaloparatide), UCB (romosozumab). BC has reported occasional interventions as an expert or speaker for Alexion, Amgen, Aptissen, Besins, Expanscience, Lilly, Kyowa-Kirin,Sublimed, Theramex, UCB, Viatris. ADP has received speaker and consultant fees from Theramex. PRE has received research funding from Amgen, Sanofi and Alexion, and speaker fees from Amgen, Alexion and Kyowa Kirin. CC has received lecture fees and honoraria from Amgen, Danone, Eli Lilly, GSK, Kyowa Kirin, Medtronic, Merck, Nestlé, Novartis, Pfizer, Roche, Servier, Shire, Takeda and UCB outside of the submitted work.The other authors did not any competing interests for this work.